ME03497B - Kombinacija koja sadrži inhibitor mek i inhibitor b-raf - Google Patents

Kombinacija koja sadrži inhibitor mek i inhibitor b-raf

Info

Publication number
ME03497B
ME03497B MEP-2019-236A MEP2019236A ME03497B ME 03497 B ME03497 B ME 03497B ME P2019236 A MEP2019236 A ME P2019236A ME 03497 B ME03497 B ME 03497B
Authority
ME
Montenegro
Prior art keywords
inhibitor
combination
raf
mek
mek inhibitor
Prior art date
Application number
MEP-2019-236A
Other languages
German (de)
English (en)
French (fr)
Inventor
Melissa Dumble
Rakesh Kumar
Sylvie Laquerre
Peter Lebowitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43876568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03497(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ME03497B publication Critical patent/ME03497B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
MEP-2019-236A 2009-10-16 2010-10-15 Kombinacija koja sadrži inhibitor mek i inhibitor b-raf ME03497B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25221309P 2009-10-16 2009-10-16
PCT/US2010/052808 WO2011047238A1 (en) 2009-10-16 2010-10-15 Combination
EP10824148.0A EP2488033B1 (en) 2009-10-16 2010-10-15 Combination comprising an MEK inhibitor and a B-raf inhibitor

Publications (1)

Publication Number Publication Date
ME03497B true ME03497B (me) 2020-04-20

Family

ID=43876568

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-236A ME03497B (me) 2009-10-16 2010-10-15 Kombinacija koja sadrži inhibitor mek i inhibitor b-raf

Country Status (33)

Country Link
US (3) US8703781B2 (me)
EP (3) EP4159217A1 (me)
JP (1) JP5718929B2 (me)
KR (1) KR101729116B1 (me)
CN (1) CN102655753B (me)
AU (1) AU2010306653B2 (me)
BR (1) BR112012008854B8 (me)
CA (1) CA2775803C (me)
CL (1) CL2012000964A1 (me)
CO (1) CO6531498A2 (me)
CR (1) CR20120155A (me)
CY (1) CY1122013T1 (me)
DK (2) DK3560498T3 (me)
DO (1) DOP2012000091A (me)
EA (1) EA020589B1 (me)
ES (2) ES2930157T3 (me)
HR (2) HRP20221304T1 (me)
HU (2) HUE046139T2 (me)
IL (1) IL219073A (me)
LT (2) LT3560498T (me)
MA (1) MA33746B1 (me)
ME (1) ME03497B (me)
MX (1) MX2012004413A (me)
MY (1) MY174759A (me)
NZ (1) NZ598913A (me)
PE (1) PE20121093A1 (me)
PL (2) PL2488033T3 (me)
PT (2) PT2488033T (me)
RS (2) RS63702B1 (me)
SI (1) SI2488033T1 (me)
UA (1) UA105064C2 (me)
WO (1) WO2011047238A1 (me)
ZA (1) ZA201202612B (me)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110022672A (ko) 2008-06-16 2011-03-07 유니버시티 오브 테네시 리서치 파운데이션 암 치료용 화합물
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
WO2011112678A1 (en) * 2010-03-09 2011-09-15 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
JP2014505658A (ja) * 2010-11-05 2014-03-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 癌を治療する方法
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
US20150010544A1 (en) 2011-12-16 2015-01-08 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
JP2015503503A (ja) * 2011-12-22 2015-02-02 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Ｂｒａｆ阻害剤および／またはｍｅｋ阻害剤とともにｍａｇｅａ３免疫療法薬を用いた癌の治療方法
US20150126533A1 (en) * 2012-03-30 2015-05-07 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
CN107308164A (zh) * 2012-09-04 2017-11-03 诺华股份有限公司 辅助癌症治疗的方法
EP2911673A4 (en) * 2012-10-25 2016-05-18 Novartis Ag COMBINATION
CN107970214A (zh) 2012-11-30 2018-05-01 葛兰素史克公司 新型药物组合物
CN103965170A (zh) * 2013-01-24 2014-08-06 通化济达医药有限公司 苯磺酰胺吡唑激酶抑制剂
MX2015011713A (es) 2013-03-05 2016-05-09 Univ Tennessee Res Foundation Compuestos para el tratamiento de cancer.
US10010608B2 (en) * 2013-05-31 2018-07-03 Merck Sharp & Dohme Corp. Combination therapies for cancer
CA2909052A1 (en) * 2013-06-03 2014-12-11 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
CN104540822B (zh) * 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
WO2015059677A1 (en) * 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
CN103588767B (zh) * 2013-11-20 2016-01-20 苏州明锐医药科技有限公司 达拉菲尼的制备方法
BR112016011222A2 (pt) * 2013-12-12 2017-09-19 Novartis Ag Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer
JP6571665B2 (ja) 2013-12-28 2019-09-04 ガーダント ヘルス， インコーポレイテッド 遺伝的バリアントを検出するための方法およびシステム
WO2015105822A1 (en) * 2014-01-07 2015-07-16 Glaxosmithkline Llc Cancer treatment method
EP3139919B1 (en) 2014-05-06 2020-06-03 Oncternal Therapeutics, Inc Compounds for treatment of cancer
KR101629184B1 (ko) 2014-12-10 2016-06-13 현대오트론 주식회사 Autosar 플랫폼에서의 eeprom 처리속도 향상을 위한 주기함수 호출 방법
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
CA3042697A1 (en) * 2016-11-03 2018-05-11 The Regents Of The University Of Michigan Small molecule dual inhibitors of egfr/pi3k and uses thereof
WO2020079581A1 (en) 2018-10-16 2020-04-23 Novartis Ag Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020323033A1 (en) * 2019-07-26 2021-04-22 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
JP2023506768A (ja) 2019-12-12 2023-02-20 ティン セラピューティックス エルエルシー 聴覚損失の予防及び治療のための組成物及び方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021168283A1 (en) * 2020-02-19 2021-08-26 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
CA3236424A1 (en) * 2021-11-02 2023-05-11 Verastem, Inc. Methods of treating abnormal cell growth
WO2023105286A1 (en) 2021-12-06 2023-06-15 My Personal Therapeutics Ltd A combination treatment for cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
JP2003514906A (ja) * 1999-11-22 2003-04-22 スミスクライン ビーチャム パブリック リミテッド カンパニー イミダゾール誘導体およびｒａｆキナーゼ阻害剤としてのその使用
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
RU2364596C2 (ru) * 2004-06-11 2009-08-20 Джапан Тобакко Инк. ПРОИЗВОДНЫЕ 5-АМИНО-2,4,7-ТРИОКСО-3,4,7,8-ТЕТРАГИДРО-2Н-ПИРИДО[2,3-d] ПИРИМИДИНА, ОБЛАДАЮЩИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
CA2924436A1 (en) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
AU2010306653B2 (en) 2013-10-24
EP2488033A4 (en) 2014-04-30
MY174759A (en) 2020-05-13
HUE060206T2 (hu) 2023-02-28
CL2012000964A1 (es) 2012-08-31
US20120196879A1 (en) 2012-08-02
HUE046139T2 (hu) 2020-02-28
PT2488033T (pt) 2019-09-10
PL3560498T3 (pl) 2022-12-12
MA33746B1 (fr) 2012-11-01
EP3560498B1 (en) 2022-08-17
JP5718929B2 (ja) 2015-05-13
JP2013508294A (ja) 2013-03-07
UA105064C2 (uk) 2014-04-10
US8952018B2 (en) 2015-02-10
MX2012004413A (es) 2012-05-08
CO6531498A2 (es) 2012-09-28
DOP2012000091A (es) 2013-09-15
CR20120155A (es) 2012-07-05
ES2930157T3 (es) 2022-12-07
EA020589B1 (ru) 2014-12-30
RS63702B1 (sr) 2022-11-30
BR112012008854B1 (pt) 2020-12-29
CA2775803A1 (en) 2011-04-21
US20150111904A1 (en) 2015-04-23
SI2488033T1 (sl) 2019-10-30
NZ598913A (en) 2013-11-29
AU2010306653A1 (en) 2012-05-10
CN102655753A (zh) 2012-09-05
LT2488033T (lt) 2019-09-10
KR20120104547A (ko) 2012-09-21
PE20121093A1 (es) 2012-09-04
PL2488033T3 (pl) 2019-12-31
EP2488033B1 (en) 2019-06-12
EA201290149A1 (ru) 2012-11-30
BR112012008854B8 (pt) 2021-05-25
US8703781B2 (en) 2014-04-22
DK3560498T3 (da) 2022-11-14
RS59181B1 (sr) 2019-10-31
LT3560498T (lt) 2022-11-25
DK2488033T3 (da) 2019-09-02
BR112012008854A2 (pt) 2015-09-22
CY1122013T1 (el) 2020-10-14
IL219073A (en) 2016-05-31
ZA201202612B (en) 2013-09-25
CN102655753B (zh) 2015-11-25
EP2488033A1 (en) 2012-08-22
HRP20221304T1 (hr) 2022-12-23
WO2011047238A1 (en) 2011-04-21
US20140187566A1 (en) 2014-07-03
ES2745479T3 (es) 2020-03-02
HRP20191617T1 (hr) 2019-12-13
EP4159217A1 (en) 2023-04-05
EP3560498A1 (en) 2019-10-30
CA2775803C (en) 2017-11-21
KR101729116B1 (ko) 2017-05-02
PT3560498T (pt) 2022-11-03
IL219073A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
SI2488033T1 (sl) Kombinacija, ki vsebuje inhibitor MEK in inhibitor B-RAF
ZA201202618B (en) Combinations of a p13k inhibitor and a mek inhibitor
PL2328784T3 (pl) Połączenie ramienia wycieraczki z piórem wycieraczki oraz pióro wycieraczki
ZA201204700B (en) Optimized endonucleases and uses thereof
EP2443259A4 (en) BIOMARKERS FOR AUTISM AND USES THEREOF
GB2469720B (en) Join-us call-log and call-answer messages
EP2429624A4 (en) EXPANDABLE DEVICES AND METHOD THEREFOR
EP2441383A4 (en) DEVICE AND METHOD FOR DETERMINING AN OBJECT TO BE FIXED
EP2490077A4 (en) ELECTRIFICATION ELEMENT AND ELECTROPHOTOGRAPHIC DEVICE
IL217761A0 (en) Dilator and assembly comprising such a dilator
EP2517684A4 (en) AIRWAY OPENING TOOL AND AIRWAY OPENING UNIT THEREWITH
EP2513654A4 (en) LABELING AND AUTHENTICATION USING A MICRO-LABEL
HK1174435A1 (zh) 磁性部件和電子元件
EP2399993A4 (en) STREPTAVIDINE HYPO-IMMUNOGEN AND USE THEREOF
GB0908280D0 (en) Trackbed liner and related methods
GB2473864B (en) Improved mouthguard and tool
EP2419091A4 (en) NANOCANAL DEVICE AND RELATED METHODS
GB0912744D0 (en) Methods and uses
GB0909380D0 (en) Method and use
GB0920642D0 (en) Anchor and methods
EP2443622A4 (en) CURRENT CONTROLLED PIXEL CIRCUITS AND ASSOCIATED METHODS
TWM374132U (en) Hard disk fixing device and electronic device
EP2291396A4 (en) MODIFIED GALECTIN-2 AND USES THEREOF
GB0916070D0 (en) Power and data unit
IL216594A0 (en) Proteasome inhibitors and uses thereof